Short answer
ARS Pharmaceuticals, Inc. (SPRY) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $34M (up 114.2% year over year) with net income of −$62M.
Q2 2026 key financials · XBRL
- Revenue
- $34M
- +114.2% YoY · +48.4% QoQ
- Net income
- −$62M
- −38.9% YoY · −2.8% QoQ
- Operating margin
- -182.6%
- EPS (diluted)
- −$0.63
- −40.0% YoY · −3.3% QoQ
Source: XBRL data from the ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 10-Q on SEC EDGAR. USD.
ARS Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Filing text contains no quarterly revenue, YoY comparison, or profitability percentages
- Filing text contains no segment or product-line performance figures
- Filing text contains no cash position, operating cash flow, or capital deployment figures
- Outlook: neffy commercialization, market acceptance, coverage, regulatory reviews, and cash-flow break-even timing
- Headwinds: competition, reimbursement, third-party dependence, funding needs, trade barriers, and significant operating losses
Risk Factors
- Generic-entry litigation triggered by Lupin and Cipla ANDA filings, with lawsuits filed through April 2026
- No U.S. non-patent exclusivity for neffy, increasing exposure to generic competition
- neffy commercialization concentrated in one approved product, making adoption and reimbursement critical to near-term revenue
- Post-commercialization safety data from a larger patient population could prompt labeling changes or market withdrawal
- Competition from established injectable epinephrine products and emerging intranasal candidates could limit market acceptance
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARS Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.